Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead o...( - On track to have Phase 3 data ...),Health

- On track to have Phase 3 data available by the spring of 2009 - - Filing of global marketing authorization applications expected by the

fall of 2009 -

ROCKVILLE, Md., Aug. 28 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has completed enrollment and initial dosing ahead of schedule in ACHIEVE 1, the first of two pivotal Phase 3 trials of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in treatment-naive patients with chronic hepatitis C. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"We have completed enrollment in the ACHIEVE 1 trial ahead of schedule and now expect to have Phase 3 data available for Albuferon by the spring of 2009, with global marketing applications anticipated in the fall of 2009," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Assuming success in Phase 3 trials, we believe that Albuferon could become the interferon of choice in treatment regimens for hepatitis C."

HGS previously projected enrollment of both Phase 3 trials by the end of 2007. A total of 1331 patients at 150 clinical sites in 12 countries have been enrolled and randomized in ACHIEVE 1, which is being conducted in treatment-naive patients with genotype 1 chronic hepatitis C. ACHIEVE 2/3 was initiated in February 2007, and will enroll and randomize a minimum of 918 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. Enrollmen
'/>"/>